{"organizations": [], "uuid": "3a64599529cf70ef6763c8b67a927e026cdd560f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 1, "shares": 1, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/us-impax-labs-m-a-amneal/u-s-ftc-requires-amneal-and-impax-to-divest-rights-to-10-generic-drugs-idUSKBN1HY2XQ", "country": "US", "domain_rank": 408, "title": "U.S. FTC requires Amneal and Impax to divest rights to 10 generic drugs", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-28T00:11:00.000+03:00", "replies_count": 0, "uuid": "3a64599529cf70ef6763c8b67a927e026cdd560f"}, "author": "", "url": "https://www.reuters.com/article/us-impax-labs-m-a-amneal/u-s-ftc-requires-amneal-and-impax-to-divest-rights-to-10-generic-drugs-idUSKBN1HY2XQ", "ord_in_thread": 0, "title": "U.S. FTC requires Amneal and Impax to divest rights to 10 generic drugs", "locations": [], "entities": {"persons": [{"name": "lisa lambert", "sentiment": "none"}, {"name": "eric beech", "sentiment": "none"}], "locations": [{"name": "washington", "sentiment": "none"}], "organizations": [{"name": "u.s. ftc", "sentiment": "negative"}, {"name": "amneal", "sentiment": "negative"}, {"name": "impax", "sentiment": "negative"}, {"name": "ani pharmaceuticals inc", "sentiment": "none"}, {"name": "impax laboratories inc", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "ftc", "sentiment": "none"}, {"name": "amneal pharmaceuticals llc", "sentiment": "none"}, {"name": "perrigo company plc", "sentiment": "none"}, {"name": "g&w laboratories inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "u.s. federal trade commission", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "WASHINGTON (Reuters) - The U.S. Federal Trade Commission said on Friday it would require Impax Laboratories Inc and privately held Amneal Pharmaceuticals LLC to divest rights to 10 generic medications as a condition of their merger.\nThe FTC said that under the terms of the proposed settlement ANI Pharmaceuticals Inc will acquire seven products, Perrigo Company Plc will acquire Impax’s rights to two products that it had partnered with Impax to manufacture and sell, and G&W Laboratories Inc will acquire Impax’s marketing rights to one product that G&W manufactures for Impax.\nReporting by Eric Beech; Editing by Lisa Lambert\n ", "external_links": [], "published": "2018-04-28T00:11:00.000+03:00", "crawled": "2018-04-28T00:26:39.006+03:00", "highlightTitle": ""}